Plk1 Inhibitors in Cancer Therapy: From Laboratory to Clinics

Overview

Journal Mol Cancer Ther

Date 2016 Jun 23

PMID 27330107

Citations 202

Authors

Rosie Elizabeth Ann Gutteridge

Mary Ann Ndiaye

Xiaoqi Liu

Nihal Ahmad

Affiliations

Soon will be listed here.

Abstract

Polo-like kinase 1 (Plk1) overexpression has been shown to occur in a wide range of tumors, prompting research and development of Plk1 inhibitors as a means of cancer treatment. This review discusses recent advances in the development of Plk1 inhibitors for cancer management. Plk1 inhibition has been shown to cause mitotic block and apoptosis of cells with higher mitotic index and therefore higher Plk1 expression. The potential of Plk1 inhibitors as cancer therapeutics has been widely investigated. However, a complete understanding of Plk1 biology/mechanism is yet to be fully achieved. Resistance to certain chemotherapeutic drugs has been linked to Plk1 overexpression, and Plk1-mediated mitotic events such as microtubule rearrangement have been found to reduce the efficacy of chemotherapeutic agents. The Plk1 inhibitor volasertib has shown considerable promise in clinical studies, having reached phase III trials. However, preclinical success with Plk1 inhibitors has not translated well into clinical success. In our view, combined therapies targeting other relevant pathways together with Plk1 may be vital to combat issues observed with monotherapy, especially resistance. In addition, research should also be directed toward understanding the mechanisms of Plk1 and designing additional next generations of specific, potent Plk1 inhibitors to target cancer. Mol Cancer Ther; 15(7); 1427-35. ©2016 AACR.

Citing Articles

Discovery of a novel PLK1 inhibitor with high inhibitory potency using a combined virtual screening strategy.

Xu Z, Guan L, Wang Y, Niu M, Ruan Y, Xu C J Enzyme Inhib Med Chem. 2025; 40(1):2467798.

PMID: 40052927 PMC: 11892073. DOI: 10.1080/14756366.2025.2467798.

Cyclin E1 overexpression sensitizes ovarian cancer cells to WEE1 and PLK1 inhibition.

Xi Q, Kunita A, Ogawa M, Ka M, Tanimoto S, Tsuchimochi S Oncogene. 2025; .

PMID: 39994376 DOI: 10.1038/s41388-025-03312-4.

A Bait-and-Hook Hydrogel for Net Tumor Cells to Enhance Chemotherapy and Mitigate Metastatic Dissemination.

Chen C, Liu J, Zhang H, Zhang H, Liang Y, Ye Q Pharmaceutics. 2025; 16(12.

PMID: 39771496 PMC: 11728792. DOI: 10.3390/pharmaceutics16121516.

Only Infant -Rearranged Leukemia Is Susceptible to an Inhibition of Polo-like Kinase 1 (PLK-1) by Volasertib.

Fischer J, Erkner E, Radszuweit P, Hentrich T, Keppeler H, Korkmaz F Int J Mol Sci. 2024; 25(23).

PMID: 39684470 PMC: 11641557. DOI: 10.3390/ijms252312760.

The Role of Polo-Like Kinase 1 (PLK1) O-GlcNAcylation in Mitosis.

Li J, Shao G, Peng B, Xu X, Dong M, Li J Methods Mol Biol. 2024; 2874:127-137.

PMID: 39614052 DOI: 10.1007/978-1-0716-4236-8_11.

References

Foretz M, Guigas B, Bertrand L, Pollak M, Viollet B . Metformin: from mechanisms of action to therapies. Cell Metab. 2014; 20(6):953-66. DOI: 10.1016/j.cmet.2014.09.018. View

Weger S, Hammer E, Heilbronn R . Topors acts as a SUMO-1 E3 ligase for p53 in vitro and in vivo. FEBS Lett. 2005; 579(22):5007-12. DOI: 10.1016/j.febslet.2005.07.088. View

Liu X, Li H, Song B, Liu X . Polo-like kinase 1 phosphorylation of G2 and S-phase-expressed 1 protein is essential for p53 inactivation during G2 checkpoint recovery. EMBO Rep. 2010; 11(8):626-32. PMC: 2920445. DOI: 10.1038/embor.2010.90. View

Olsen T, Palejwala N, Lee L, Bergstrom C, Yeh S . Chorioretinal folds: associated disorders and a related maculopathy. Am J Ophthalmol. 2014; 157(5):1038-47. DOI: 10.1016/j.ajo.2014.02.021. View

Stehle A, Hugle M, Fulda S . Eribulin synergizes with Polo-like kinase 1 inhibitors to induce apoptosis in rhabdomyosarcoma. Cancer Lett. 2015; 365(1):37-46. DOI: 10.1016/j.canlet.2015.04.011. View

Posch C, Cholewa B, Vujic I, Sanlorenzo M, Ma J, Kim S . Combined Inhibition of MEK and Plk1 Has Synergistic Antitumor Activity in NRAS Mutant Melanoma. J Invest Dermatol. 2015; 135(10):2475-2483. PMC: 4567913. DOI: 10.1038/jid.2015.198. View

Mross K, Dittrich C, Aulitzky W, Strumberg D, Schutte J, Schmid R . A randomised phase II trial of the Polo-like kinase inhibitor BI 2536 in chemo-naïve patients with unresectable exocrine adenocarcinoma of the pancreas - a study within the Central European Society Anticancer Drug Research (CESAR) collaborative.... Br J Cancer. 2012; 107(2):280-6. PMC: 3394983. DOI: 10.1038/bjc.2012.257. View

Rajendra R, Malegaonkar D, Pungaliya P, Marshall H, Rasheed Z, Brownell J . Topors functions as an E3 ubiquitin ligase with specific E2 enzymes and ubiquitinates p53. J Biol Chem. 2004; 279(35):36440-4. DOI: 10.1074/jbc.C400300200. View

Shin S, Woo S, Yim H . Differential Cellular Effects of Plk1 Inhibitors Targeting the ATP-binding Domain or Polo-box Domain. J Cell Physiol. 2015; 230(12):3057-67. DOI: 10.1002/jcp.25042. View

10.

Olmos D, Barker D, Sharma R, Brunetto A, Yap T, Taegtmeyer A . Phase I study of GSK461364, a specific and competitive Polo-like kinase 1 inhibitor, in patients with advanced solid malignancies. Clin Cancer Res. 2011; 17(10):3420-30. DOI: 10.1158/1078-0432.CCR-10-2946. View

11.

de Braud F, Cascinu S, Spitaleri G, Pilz K, Clementi L, Liu D . A phase I, dose-escalation study of volasertib combined with nintedanib in advanced solid tumors. Ann Oncol. 2015; 26(11):2341-6. DOI: 10.1093/annonc/mdv354. View

12.

Gumireddy K, Reddy M, Cosenza S, Boominathan R, Boomi Nathan R, Baker S . ON01910, a non-ATP-competitive small molecule inhibitor of Plk1, is a potent anticancer agent. Cancer Cell. 2005; 7(3):275-86. DOI: 10.1016/j.ccr.2005.02.009. View

13.

Brassesco M, Pezuk J, Morales A, de Oliveira J, Roberto G, Silva G . In vitro targeting of Polo-like kinase 1 in bladder carcinoma: comparative effects of four potent inhibitors. Cancer Biol Ther. 2013; 14(7):648-57. PMC: 3742494. DOI: 10.4161/cbt.25087. View

14.

Chan A . Metformin for cancer prevention: a reason for optimism. Lancet Oncol. 2016; 17(4):407-409. DOI: 10.1016/S1470-2045(16)00006-1. View

15.

Lin C, Su W, Yen C, Hsu C, Su W, Yeh K . A phase I study of two dosing schedules of volasertib (BI 6727), an intravenous polo-like kinase inhibitor, in patients with advanced solid malignancies. Br J Cancer. 2014; 110(10):2434-40. PMC: 4021529. DOI: 10.1038/bjc.2014.195. View

16.

Monte M, Benetti R, Collavin L, Marchionni L, Del Sal G, Schneider C . hGTSE-1 expression stimulates cytoplasmic localization of p53. J Biol Chem. 2004; 279(12):11744-52. DOI: 10.1074/jbc.M311123200. View

17.

Frost A, Mross K, Steinbild S, Hedbom S, Unger C, Kaiser R . Phase i study of the Plk1 inhibitor BI 2536 administered intravenously on three consecutive days in advanced solid tumours. Curr Oncol. 2012; 19(1):e28-35. PMC: 3267594. DOI: 10.3747/co.19.866. View

18.

Hou X, Li Z, Huang W, Li J, Staiger C, Kuang S . Plk1-dependent microtubule dynamics promotes androgen receptor signaling in prostate cancer. Prostate. 2013; 73(12):1352-63. PMC: 3720713. DOI: 10.1002/pros.22683. View

19.

Song B, Liu X, Davis K, Liu X . Plk1 phosphorylation of Orc2 promotes DNA replication under conditions of stress. Mol Cell Biol. 2011; 31(23):4844-56. PMC: 3232917. DOI: 10.1128/MCB.06110-11. View

20.

Li Z, Li J, Bi P, Lu Y, Burcham G, Elzey B . Plk1 phosphorylation of PTEN causes a tumor-promoting metabolic state. Mol Cell Biol. 2014; 34(19):3642-61. PMC: 4187734. DOI: 10.1128/MCB.00814-14. View